Evidence map›Paper›PMID 31485669›Full record

ArticleMolecular medicine reports2019

COX‑2 promotes epithelial‑mesenchymal transition and migration in osteosarcoma MG‑63 cells via PI3K/AKT/NF‑κB signaling.

Xueliang Zhang, Peng Qu, Hui Zhao, Tong Zhao, Nong Cao

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. MicroRNA-181a-5p Promotes Osteosarcoma Progression via PTEN/AKT Pathway.Analytical cellular pathology (Amsterdam) · 2022
    Article
  16. Article
  17. Anticancer and Anti-Inflammatory Mechanisms of NOSH-Aspirin and Its Biological Effects.Computational and mathematical methods in medicine · 2022
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Xueliang ZhangDepartment of Osteology, The Lanzhou University Second Hospital, Lanzhou, Gansu 730030, P.R. China.
Peng QuDepartment of Osteology, The First Hospital of Lanzhou University, Lanzhou, Gansu 730030, P.R. China.
Hui ZhaoDepartment of Osteology, The First Hospital of Lanzhou University, Lanzhou, Gansu 730030, P.R. China.
Tong ZhaoDepartment of Osteology, The First Hospital of Lanzhou University, Lanzhou, Gansu 730030, P.R. China.
Nong CaoDepartment of General Surgery, The First Hospital of Lanzhou University, Lanzhou, Gansu 730030, P.R. China.
Lanzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present study aimed to investigate the mechanism by which cyclooxygenase‑2 (COX‑2) promotes the metastasis of MG‑63 osteosarcoma cells through the PI3K/AKT/NF‑κB pathway. To achieve this, a recombinant lentivirus containing the COX‑2 gene was constructed in order to overexpress COX‑2; a recombinant lentivirus containing a control sequence was also constructed. A Transwell chamber migration assay was performed to quantify the migration of the COX‑2‑transduced cells, and of cells treated with a COX‑2 inhibitor (NS398) or a PI3K inhibitor (LY294002). Immunofluorescence assays were performed to determine changes in E‑cadherin, vimentin and NF‑κB expression levels. ELISAs were performed to quantify the levels of matrix metallopeptidase (MMP)‑2, MMP‑9 and vascular endothelial growth factor (VEGF) in the culture medium. Western blot analysis was conducted to measure the protein expression levels of MMP‑2, MMP‑9, PI3K, phosphorylated (p‑) PI3K, AKT, p‑AKT, inhibitor of NF‑κΒ kinase (IKK) and p‑IKK. The results demonstrated that the migration ability of the COX‑2‑overexpressing MG‑63 cells was significantly increased compared with the control cells. The migration ability of cells treated with NS398 or LY294002 was significantly decreased. Compared with the control cells, E‑cadherin expression was significantly decreased in COX‑2‑overexpressing cells, while the expression levels of vimentin, MMP‑2, MMP‑9, VEGF, p‑PI3K, p‑AKT and p‑IKK were significantly increased. Compared with the control cells, E‑cadherin expression was significantly increased in cells treated with NS398 or LY294002, while the expression levels of vimentin, MMP‑2, MMP‑9, VEGF, p‑PI3K, p‑AKT, and p‑IKK were significantly decreased. The total protein levels of PI3K, AKT and IKK were not changed among the treatment groups. In summary, COX‑2 overexpression decreased the expression levels of the epithelial protein E‑cadherin and increased the expression levels of the mesenchymal proteins vimentin, MMP‑2 and MMP‑9, as well as promoted cell migration, by activating the PI3K/AKT/NF‑κB signaling pathway.

Indexed as

Epithelial-Mesenchymal TransitionSignal TransductionBone NeoplasmsCell LineCell Line, TumorCyclooxygenase 2HumansNF-kappa BOsteosarcomaPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktCyclooxygenase 2NF-kappa BPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-akt

Identifiers

PMID31485669
PMCPMC6755176
OpenAlexW2969588014

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.